Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial

Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial

Abstract Endocrine therapy is recommended for patients with hormone receptor-positive (HR+) advanced and metastatic breast cancer without visceral crisis (symptomatic visceral disease). However, many patients experience disease progression during treatment, and most patients eventually develop endoc...

Full description

Bibliographic Details
Main Author: Gabriel N. Hortobagyi
Format: Article
Language:English
Published: BMC 2018-10-01
Series:Breast Cancer Research
Subjects:
CDK4/6 inhibitor
Ribociclib
Endocrine therapy
Hormone receptor-positive
HR+/HER2− breast cancer
MONALEESA-2
Online Access:http://link.springer.com/article/10.1186/s13058-018-1050-7

Internet

http://link.springer.com/article/10.1186/s13058-018-1050-7

Similar Items